Tirzepatide vs. semaglutide: what the clinical data actually shows

What did @thewellness_np actually say?

Honestly? Not much. The transcript from this video is almost entirely song lyrics, specifically what appears to be a remix or parody built around the phrase 'game changer.' The creator's caption promises a breakdown of tirzepatide versus semaglutide, describing both as 'groundbreaking treatments that have changed the game in weight loss.' But the actual spoken content delivers zero clinical information. What we got was: 'Right in sea is gonna be a game changer, a game changer.' That's it.

To be fair, the caption does frame this as an explainer video, and the creator identifies as an NP (nurse practitioner). But a caption is not medical education. If the substance of a health claim lives entirely in the hashtags and the description box, there's nothing substantive to fact-check, and arguably nothing useful for the viewer either. We'll evaluate the claims made in the caption and framing since that's what the audience is responding to.

Does the science back this up?

The caption's core claim, that both drugs have 'changed the game in weight loss,' is actually defensible. But defensible is not the same as precise, and precision matters here.

Semaglutide (the active ingredient in Wegovy for obesity, Ozempic for type 2 diabetes) works as a GLP-1 receptor agonist. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed a mean body weight reduction of 14.9% over 68 weeks in adults with obesity. That is a real and clinically significant result, especially compared to what lifestyle intervention alone typically achieves.

Tirzepatide goes further mechanistically. It targets both GLP-1 and GIP receptors, a dual agonist approach. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed weight loss up to 22.5% at the highest dose over 72 weeks. A head-to-head comparison (SURPASS-2, Frías et al., 2021, NEJM) found tirzepatide outperformed semaglutide on HbA1c and body weight in type 2 diabetes patients, though that trial used semaglutide 1.0 mg, not the 2.4 mg Wegovy dose used for obesity.

So yes, both drugs represent a real shift in what's medically achievable for weight management. The science supports that framing. What it doesn't support is the implication that any viewer can determine which drug is right for them based on a TikTok.

What did they get wrong (or right)?

The caption gets one thing right: understanding your options does matter. Patients who walk into a clinical consultation with some baseline knowledge tend to have better conversations with their providers. Credit where it's due.

What's wrong, or at least irresponsible, is the format. A song-lyric video that promises a clinical comparison and delivers none is not education. It's engagement farming using medical credibility as the hook. The creator's NP credential lends the caption authority it hasn't earned in this particular video.

The phrase 'how do you know which one might be right for you' (from the caption) is where I'd pump the brakes hardest. That question requires a real clinical evaluation: metabolic history, cardiovascular risk, insurance coverage, tolerance of GI side effects, prior medication history. No TikTok answers that. Framing it as something a viewer can figure out from a social media video, even a well-intentioned one, is a problem.

What should you actually know?

Here's the actual comparison, since the video didn't provide one.

• Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 and GIP receptor agonist. That dual mechanism is likely why tirzepatide shows greater average weight loss in trials.
• Both are injectable, weekly medications. Both carry GI side effects including nausea, vomiting, and constipation, particularly during dose escalation.
• Neither is a cure for obesity. Both require continued use to maintain weight loss. Wilding et al. (2022, Diabetes, Obesity and Metabolism) showed significant weight regain after stopping semaglutide.
• Compounded versions of both drugs exist and are legally distinct from FDA-approved brand-name products. Efficacy and safety data from clinical trials apply to the approved formulations, not compounded alternatives.
• Which drug is appropriate for a given patient depends on clinical factors that a provider needs to evaluate. A TikTok cannot make that determination.